Valeant’s Acquires Medicis & Could Dominate The US Dermatology MarketVW Staff
Valeant Pharmaceuticals Int (NYSE:VRX) (TSE:VRX) announced on Labor Day, a deal to acquire Medicis Pharmaceutical Corp (NYSE:MRX) in a $2.6 billion deal.
The Medicis shareholders would be paid $44 in cash per share held, marking a premium of 39% over the closing price of their stock on Friday.
Medicis Pharmaceutical Corp (NYSE:MRX) was the market leader in dermatology . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.